Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Instil Bio's share price for the quarter that ended in Dec. 2023 was $7.62. Instil Bio's Shares Outstanding (EOP) for the quarter that ended in Dec. 2023 was 6.50 Mil. Therefore, Instil Bio's market cap for the quarter that ended in Dec. 2023 was $49.56 Mil.
Instil Bio's quarterly market cap
declined
from Jun. 2023 ($71.67 Mil) to Sep. 2023 ($55.67 Mil) and
declined
from Sep. 2023 ($55.67 Mil) to Dec. 2023 ($49.56 Mil).
Instil Bio's annual market cap
declined
from Dec. 2021 ($2,207.67 Mil) to Dec. 2022 ($81.95 Mil) and
declined
from Dec. 2022 ($81.95 Mil) to Dec. 2023 ($49.56 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Instil Bio's Enterprise Value for Today is $4.64 Mil.
Instil Bio Market Cap Historical Data
The historical data trend for Instil Bio's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Instil Bio's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Instil Bio's Market Cap Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Instil Bio's Market Cap distribution charts can be found below:
* The bar in red indicates where Instil Bio's Market Cap falls into.
Instil Bio Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Instil Bio's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Instil Bio (NAS:TIL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Instil Bio Market Cap Related Terms
Thank you for viewing the detailed overview of Instil Bio's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.
Instil Bio Inc is a clinical-stage biopharmaceutical company focused on developing an innovative cell therapy pipeline of autologous tumor infiltrating lymphocyte, or TIL, therapies for the treatment of patients with cancer. It is also engaged in developing a novel class of genetically engineered TIL therapies using our Co-Stimulatory Antigen Receptor, or CoStAR, platform. The company's lead product candidate, ITIL-168, is an autologous TIL therapy that it is initially developing for the treatment of PD-1-inhibitor relapsed or refractory advanced melanoma.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
TIL has been successfully added to your 